

New Vaccine Post-Introduction Evaluation (PIE) Tool

Immunization, Vaccines and Biologicals



**World Health
Organization**

New Vaccine Post-Introduction Evaluation (PIE) Tool

Immunization, Vaccines and Biologicals



**World Health
Organization**

**The Department of Immunization, Vaccines and Biologicals
thanks the donors whose unspecified financial support
has made the production of this document possible.**

This publication was produced by the
Expanded Program on Immunization (EPI)
of the Department of Immunization, Vaccines and Biologicals

*Ordering code: WHO/IVB/10.03
July 2010*

This publication is available on the Internet at:
www.who.int/vaccines-documents/

**Copies of this document as well as additional materials on
immunization, vaccines and biologicals may be requested from:**

World Health Organization
Department of Immunization, Vaccines and Biologicals
CH-1211 Geneva 27, Switzerland

• *Fax:* + 41 22 791 4227 • *Email:* vaccines@who.int •

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

Contents

Abbreviations and acronyms	v
Acknowledgements.....	vi
Preface.....	vii
1. Overview.....	1
1.1 Introduction	1
1.2 What are the goals of the manual?	1
1.3 What is a PIE?	2
1.4 When and where should a PIE be done?	2
1.5 How is a PIE conducted?	3
1.6 Who should conduct a PIE?	5
1.7 How much does it cost to conduct a PIE?	6
1.8 How long should a PIE take?	6
2. Evaluation areas	8
2.1 Planning and introduction	8
2.2 Coverage, drop-out, recording and reporting.....	9
2.3 Cold-chain management.....	12
2.4 Vaccine management, transport and logistics	13
2.5 Monitoring and supervision	14
2.6 Training and knowledge of health-care workers	14
2.7 Injection safety and waste management	15
2.8 Vaccine wastage	16
2.9 Adverse events following immunization	16
2.10 Advocacy, communication and acceptance	17
3. Data synthesis and reporting	18
3.1 Data analysis	18
3.2 Recommendations.....	18
3.3 Presentation of findings at national level.....	19
4. Reference documents / websites	20

5. Appendices	21
<i>Appendix 1: Checklist of pre-PIE activities</i>	<i>21</i>
<i>Appendix 2: Questionnaires</i>	<i>22</i>
<i>Appendix 3: Suggested key findings</i>	<i>47</i>
<i>Appendix 4: Summary spreadsheet</i>	<i>48</i>
<i>Appendix 5: Summary spreadsheet</i>	<i>58</i>
<i>Appendix 6: Common problems and solutions.....</i>	<i>62</i>
<i>Appendix 7: Report outline template</i>	<i>65</i>

Abbreviations and acronyms

AD syringe	Auto-Disable Syringe
AEFI	Adverse Events Following Immunization
BCG	Bacille Calmette–Guérin (vaccine)
CDC	Centers for Disease Control and Prevention
cMYP	Comprehensive Multiyear Plan
DTP	Diphtheria–Tetanus–Pertussis (vaccine)
EPI	Expanded Programme on Immunization (WHO)
GAVI Alliance	formerly Global Alliance for Vaccines & Immunizations
HCW	Health-Care Worker
HepB	Hepatitis B
Hib	Haemophilus influenzae type b
ICC	Interagency Coordinating Committee
IEC	Information, Education and Communication
MDVP	Multi-dose Vial Policy (WHO/EPI)
MoH	Ministry of Health
NGO	Nongovernmental Organization
OPV	Oral Polio Vaccine
PCV	Pneumococcal Conjugate Vaccine
PCV7	7-Valent Pneumococcal Conjugate Vaccine
PIE	Post-Introduction Evaluation
UNICEF	United Nations Children’s Fund
VVM	Vaccine Vial Monitor
WHO	World Health Organization
YF	Yellow Fever

Acknowledgements

This Post-Introduction Evaluation tool has been derived from existing materials, reports and experiences from hepatitis B (HepB) vaccine evaluations globally, and from HepB and *Haemophilus influenzae* type b (Hib) vaccine evaluations in the WHO Regional Offices for Africa and Europe. We would like to thank those who contributed to these evaluations. The tool also draws heavily on other existing vaccine management and related documents from the World Health Organization (WHO) and United Nations Children's Fund (UNICEF), and we also thank all those involved in the preparation of these documents. In particular we acknowledge the contributions from Gavin Grant, Terri Hyde and Linda Ojo Centers for Diseases Control and Prevention (CDC) and Rosalyn O'Loughlin London School of Hygiene and Tropical Medicine (LSHTM). The tool was used in four countries during 2007 and 2008, and this experience resulted in frequent revision of the document. We would like to thank all the participants in the evaluations in Ethiopia, Liberia, Sierra Leone and Ukraine; in particular for their valuable comments on improving the tool. Similarly, we would also like to thank those reviewers who dedicated their valuable time to providing comments and suggestions on how to improve the tool.

Preface

The WHO recommends that all countries which have introduced a new vaccine should evaluate the impact on their vaccination system. Until now, this evaluation consisted of a checklist, which was considered by some to be too limited to identify problems and provide useful information to the country. This new PIE tool is more comprehensive and is akin to a mini-review of WHO's Expanded Programme on Immunization (EPI). Because EPI reviews are typically conducted on a three to five year basis, a smaller review following the introduction of a new vaccine can help with timely identification of problems and can highlight strengths of introducing a new vaccine to the EPI system. Such a review, called a Post-Introduction Evaluation (PIE), is normally conducted 6–12 months following introduction.

This post-introduction evaluation tool is designed, to assist immunization managers in countries that have introduced a new or underutilized vaccine to provide a systematic method for evaluating the implementation of the introduction, and its impact on the existing immunization system in the country. Such evaluation will allow problems associated with the introduction of the vaccine to be identified early enough to be corrected and documented, so that they can be prevented in future introductions of new vaccine(s) and shared with other countries to prevent similar problems, and also to indicate the ease or complexity of the vaccine introduction. This document may also be useful for institutions or other professionals with similar assignments and/or objectives.

This post-introduction tool is not intended to facilitate disease surveillance or monitoring of the vaccine's impact on disease burden. Specific tools for this purpose are available for rotavirus vaccine, and other tools for monitoring the impact of Hib and pneumococcal vaccines on *Haemophilus influenzae* type b and *Streptococcus pneumoniae* disease will be available from WHO in mid 2010.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28978

